Items tagged with Latent TB
One-month TB prophylaxis as effective as nine-month regimen for people living with HIV (post)
A one-month antibiotic regimen to prevent active tuberculosis (TB) disease was at least as safe and effective as the standard nine-month therapy for people living with HIV, according to the results of a large international clinical trial. Adults and adolescents in the trial were more likely to complete the short-course regimen — consisting of daily doses of the antibiotics rifapentine and isoniazid for four weeks—than the standard nine-month regimen of daily isoniazid.
Isoniazid-rifapentine for latent TB infection: a systematic review and meta-analysis (post)
A review published in the American Journal of Preventive Medicine examined the most recent evidence regarding 3-month isoniazid-rifapentine’s effectiveness, safety, and treatment completion when directly compared with other latent TB infection regimens primarily comprising 9-month isoniazid treatment.
CDC releases updated recommendations for treatment of latent TB infection (post)
The U.S. Centers for Disease Control and Prevention (CDC) has issued updated recommendations regarding the use of 3HP (once-weekly isoniazid-rifapentine for 12 weeks) for the treatment of latent tuberculosis (TB) infection.
Latent TB treatment: Shorter is better (post)
Game-changing study on treatment of latent TB shows a novel, short therapy is safer and more effective in children and adults than standard therapy.
Revisiting the timetable of tuberculosis (post)
Tuberculosis has a much shorter incubation period than is widely thought, say Marcel A Behr and colleagues, and this has implications for prioritising research and public health strategies.
The sleeping giant: the danger of neglecting latent TB infection (post)
The European Centre for Disease Prevention and Control (ECDC) has published comprehensive guidance on the management of latent tuberculosis infection (LTBI) targeted for European Union/European Economic Area (EU/EEA) countries.
Ishita Marwah: “My aim is to create innovative solutions to tackle TB" (post)
PhD student Ishita Marwah at Imperial College London won a President’s Award for Excellence in Societal Engagement for communicating the immunology of latent TB.
With a focus on high-risk patients, SLU researcher eyes eliminating TB for good (post)
In a recent paper published in PLOS One, Soumya Chatterjee, M.D., assistant professor of infectious diseases, allergy and immunology at Saint Louis University, presents data to show that a focus on high-risk tuberculosis patients may be the answer to stalled progress in stamping out the illness in the United States.
South Asians at risk for TB often are not tested (post)
Many South Asian immigrants from countries where tuberculosis (TB) is common do not get tested even though they are at high risk for developing the disease, according to a recent study by Rutgers University and St. Peter’s University Hospital.
Webinar: Treating latent TB with safer options (post)
The International Union Against Tuberculosis and Lung Disease will host a webinar on 4 February 2019 on the new safer treatment options for latent TB.
Page 6 of 13 · Total posts: 0
←First 5 6 7 Last→